1 – 10 of 35
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
-
Mark
Loss of Chromosome Y in Neuroblastoma Is Associated With High-Risk Disease, 11q-Deletion, and Telomere Maintenance
(
- Contribution to journal › Article
- 2023
-
Mark
Katedralen och muserna : De tre latinpoeterna Willich Westhoff, Bertel Knudsen Aqvilonius och Niels Tryggesen Porta
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2022
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2021
-
Mark
Evaluation of 92 cardiovascular proteins in dried blood spots collected under field-conditions : Off-the-shelf affinity-based multiplexed assays work well, allowing for simplified sample collection
(
- Contribution to journal › Article
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Bone marrow absorbed doses and correlations with hematological response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases
(
- Contribution to journal › Article